The effect of α MSH analogues on rat bones

Sungkil Lim, Song Zhe Li, Yumie Rhee, Sang Su Chung, Yong Jun Jin, Jong In Yook

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Melanocortin is the downstream mediator of leptin signaling absence of leptin signaling in ob/ob and db/db mice revealed the enhancement of bone formation through the central regulation. While alpha-melanocyte-stimulating hormone (α NISH) inhibits the secretion of interleukin-1 α and tumor necrosis factor- α from the inflammatory cells, α MSH can also enhance clonal expansion of pro B cells linked to stimulation of osteoclastogenesis. Therefore, we tested the effect of melanocortin on bones. α MSH analogues [6His] α MSH-ND and [6Asn] α MSH-ND were synthesized and the radio-ligand receptor binding- and cyclic AMP generating activity were analyzed in China Hamster Ovary cell line over- expressing melanocortin receptors. The EC50 of [6His] α MSH-ND measured from melanocortin-1, 3, 4 and 5 receptors were 0.008 ± 0.0045, 1.523 ± 0.707, 0.780 ± 0.405, 6 and 250.320 ± 42.234 nM, respectively, and the EC50 of [6Asn] α MSH-ND were 16.8 ± 6.94, 271.8 ± 21.95, 8.0 ± 1.21, and 1132.5 ± 635.46 nM, respectively. Four weeks after the subcutaneous injection of the analogues, the body weights in the [6His] α MSH-ND and the [6Asn] α MSH-ND treated groups (346.6 ± 20.63 g vs. 350.0 ± 13.57 g) were lower than that of the vehicle treated group (375.8 ± 17.31 g, p < 0.05). There was no difference in the total femoral BNM measured by dual x-ray absorptiometry among the three groups. Among the three groups, there were no differences in the total numbers of crystal violet positive- or alkaline phosphatase positive colonies, in the expression of Receptor Activator of Nuclear Factor Kappa-B ligand on the tibia and the total number of multinucleated osteoclast-like cells differentiated from primary cultured bone marrow cells. From the above results, no evidence of bone gain or loss found after treatment of the α MSH analogues peripherally.

Original languageEnglish
Pages (from-to)500-510
Number of pages11
JournalYonsei medical journal
Volume43
Issue number4
DOIs
Publication statusPublished - 2002 Jan 1

Fingerprint

Melanocyte-Stimulating Hormones
Bone and Bones
Melanocortins
Leptin
Osteogenesis
Receptor, Melanocortin, Type 3
Receptor, Melanocortin, Type 1
Melanocortin Receptors
Cyclic AMP Receptors
RANK Ligand
Gentian Violet
alpha-MSH
B-Lymphoid Precursor Cells
Osteoclasts
Subcutaneous Injections
Thigh
Tibia
Radio
Interleukin-1
Bone Marrow Cells

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Lim, Sungkil ; Li, Song Zhe ; Rhee, Yumie ; Chung, Sang Su ; Jin, Yong Jun ; Yook, Jong In. / The effect of α MSH analogues on rat bones. In: Yonsei medical journal. 2002 ; Vol. 43, No. 4. pp. 500-510.
@article{a9458c6a1be448c7b4011009e244418e,
title = "The effect of α MSH analogues on rat bones",
abstract = "Melanocortin is the downstream mediator of leptin signaling absence of leptin signaling in ob/ob and db/db mice revealed the enhancement of bone formation through the central regulation. While alpha-melanocyte-stimulating hormone (α NISH) inhibits the secretion of interleukin-1 α and tumor necrosis factor- α from the inflammatory cells, α MSH can also enhance clonal expansion of pro B cells linked to stimulation of osteoclastogenesis. Therefore, we tested the effect of melanocortin on bones. α MSH analogues [6His] α MSH-ND and [6Asn] α MSH-ND were synthesized and the radio-ligand receptor binding- and cyclic AMP generating activity were analyzed in China Hamster Ovary cell line over- expressing melanocortin receptors. The EC50 of [6His] α MSH-ND measured from melanocortin-1, 3, 4 and 5 receptors were 0.008 ± 0.0045, 1.523 ± 0.707, 0.780 ± 0.405, 6 and 250.320 ± 42.234 nM, respectively, and the EC50 of [6Asn] α MSH-ND were 16.8 ± 6.94, 271.8 ± 21.95, 8.0 ± 1.21, and 1132.5 ± 635.46 nM, respectively. Four weeks after the subcutaneous injection of the analogues, the body weights in the [6His] α MSH-ND and the [6Asn] α MSH-ND treated groups (346.6 ± 20.63 g vs. 350.0 ± 13.57 g) were lower than that of the vehicle treated group (375.8 ± 17.31 g, p < 0.05). There was no difference in the total femoral BNM measured by dual x-ray absorptiometry among the three groups. Among the three groups, there were no differences in the total numbers of crystal violet positive- or alkaline phosphatase positive colonies, in the expression of Receptor Activator of Nuclear Factor Kappa-B ligand on the tibia and the total number of multinucleated osteoclast-like cells differentiated from primary cultured bone marrow cells. From the above results, no evidence of bone gain or loss found after treatment of the α MSH analogues peripherally.",
author = "Sungkil Lim and Li, {Song Zhe} and Yumie Rhee and Chung, {Sang Su} and Jin, {Yong Jun} and Yook, {Jong In}",
year = "2002",
month = "1",
day = "1",
doi = "10.3349/ymj.2002.43.4.500",
language = "English",
volume = "43",
pages = "500--510",
journal = "Yonsei Medical Journal",
issn = "0513-5796",
publisher = "Yonsei University College of Medicine",
number = "4",

}

Lim, S, Li, SZ, Rhee, Y, Chung, SS, Jin, YJ & Yook, JI 2002, 'The effect of α MSH analogues on rat bones', Yonsei medical journal, vol. 43, no. 4, pp. 500-510. https://doi.org/10.3349/ymj.2002.43.4.500

The effect of α MSH analogues on rat bones. / Lim, Sungkil; Li, Song Zhe; Rhee, Yumie; Chung, Sang Su; Jin, Yong Jun; Yook, Jong In.

In: Yonsei medical journal, Vol. 43, No. 4, 01.01.2002, p. 500-510.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effect of α MSH analogues on rat bones

AU - Lim, Sungkil

AU - Li, Song Zhe

AU - Rhee, Yumie

AU - Chung, Sang Su

AU - Jin, Yong Jun

AU - Yook, Jong In

PY - 2002/1/1

Y1 - 2002/1/1

N2 - Melanocortin is the downstream mediator of leptin signaling absence of leptin signaling in ob/ob and db/db mice revealed the enhancement of bone formation through the central regulation. While alpha-melanocyte-stimulating hormone (α NISH) inhibits the secretion of interleukin-1 α and tumor necrosis factor- α from the inflammatory cells, α MSH can also enhance clonal expansion of pro B cells linked to stimulation of osteoclastogenesis. Therefore, we tested the effect of melanocortin on bones. α MSH analogues [6His] α MSH-ND and [6Asn] α MSH-ND were synthesized and the radio-ligand receptor binding- and cyclic AMP generating activity were analyzed in China Hamster Ovary cell line over- expressing melanocortin receptors. The EC50 of [6His] α MSH-ND measured from melanocortin-1, 3, 4 and 5 receptors were 0.008 ± 0.0045, 1.523 ± 0.707, 0.780 ± 0.405, 6 and 250.320 ± 42.234 nM, respectively, and the EC50 of [6Asn] α MSH-ND were 16.8 ± 6.94, 271.8 ± 21.95, 8.0 ± 1.21, and 1132.5 ± 635.46 nM, respectively. Four weeks after the subcutaneous injection of the analogues, the body weights in the [6His] α MSH-ND and the [6Asn] α MSH-ND treated groups (346.6 ± 20.63 g vs. 350.0 ± 13.57 g) were lower than that of the vehicle treated group (375.8 ± 17.31 g, p < 0.05). There was no difference in the total femoral BNM measured by dual x-ray absorptiometry among the three groups. Among the three groups, there were no differences in the total numbers of crystal violet positive- or alkaline phosphatase positive colonies, in the expression of Receptor Activator of Nuclear Factor Kappa-B ligand on the tibia and the total number of multinucleated osteoclast-like cells differentiated from primary cultured bone marrow cells. From the above results, no evidence of bone gain or loss found after treatment of the α MSH analogues peripherally.

AB - Melanocortin is the downstream mediator of leptin signaling absence of leptin signaling in ob/ob and db/db mice revealed the enhancement of bone formation through the central regulation. While alpha-melanocyte-stimulating hormone (α NISH) inhibits the secretion of interleukin-1 α and tumor necrosis factor- α from the inflammatory cells, α MSH can also enhance clonal expansion of pro B cells linked to stimulation of osteoclastogenesis. Therefore, we tested the effect of melanocortin on bones. α MSH analogues [6His] α MSH-ND and [6Asn] α MSH-ND were synthesized and the radio-ligand receptor binding- and cyclic AMP generating activity were analyzed in China Hamster Ovary cell line over- expressing melanocortin receptors. The EC50 of [6His] α MSH-ND measured from melanocortin-1, 3, 4 and 5 receptors were 0.008 ± 0.0045, 1.523 ± 0.707, 0.780 ± 0.405, 6 and 250.320 ± 42.234 nM, respectively, and the EC50 of [6Asn] α MSH-ND were 16.8 ± 6.94, 271.8 ± 21.95, 8.0 ± 1.21, and 1132.5 ± 635.46 nM, respectively. Four weeks after the subcutaneous injection of the analogues, the body weights in the [6His] α MSH-ND and the [6Asn] α MSH-ND treated groups (346.6 ± 20.63 g vs. 350.0 ± 13.57 g) were lower than that of the vehicle treated group (375.8 ± 17.31 g, p < 0.05). There was no difference in the total femoral BNM measured by dual x-ray absorptiometry among the three groups. Among the three groups, there were no differences in the total numbers of crystal violet positive- or alkaline phosphatase positive colonies, in the expression of Receptor Activator of Nuclear Factor Kappa-B ligand on the tibia and the total number of multinucleated osteoclast-like cells differentiated from primary cultured bone marrow cells. From the above results, no evidence of bone gain or loss found after treatment of the α MSH analogues peripherally.

UR - http://www.scopus.com/inward/record.url?scp=0036667234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036667234&partnerID=8YFLogxK

U2 - 10.3349/ymj.2002.43.4.500

DO - 10.3349/ymj.2002.43.4.500

M3 - Article

C2 - 12205739

AN - SCOPUS:0036667234

VL - 43

SP - 500

EP - 510

JO - Yonsei Medical Journal

JF - Yonsei Medical Journal

SN - 0513-5796

IS - 4

ER -